TetraScience

TetraScience Co-Founder & CTO Siping Wang joined industry leaders in a panel discussion about next-generation technology in pharma R&D and manufacturing at #PharmaIntegrates2024 this month. The panel discussed how automation, digital integration, and AI are shaping the future of pharma and patient care. Here’s what stood out: ??. ???????????????????? ??????????????????????????: Pharma labs lag behind other industries in user experience. Modernizing systems with intuitive interfaces, AI-powered workflows, and modernizing workflows for real-time collaboration is essential for closing efficiency gaps. ??. ???????????????? ???????????????????? ??????????????????????????: Rigid industrial systems are being replaced by flexible, user-centric architectures that enable seamless data flow and decision-making. Automation and digital twins hold great promise but require cultural shifts for data sharing and clear regulatory pathways. ??. ???? ???? ???????????????????? ??????????????????: AI aims to streamline experiments, optimize workflows, and assist users through AI agents and conversational UIs. Emphasis on data-driven experiments highlights the need for user-centric approaches in automation and AI applications to uncover high-value use cases. ??. ???????????????? ???????????????????? & ?????????????????????????? ????????????????????: Ensuring compliance with evolving regulations and cybersecurity standards is critical. Risk-based approaches and proactive monitoring are needed to balance innovation with patient safety. ??. ??????????????-???????????????? ????????????????????: Advances in data handling allow for tailored therapies with potentially lower side effects. Digital tools promise faster, more transparent drug development, enhancing patient outcomes. ???????????? ?????????? ?????? ?????? ????????????????: ? Modernize lab systems and adopt FAIR data standards. ? Leverage AI/ML to optimize lab operations. ? Collaborate with vendors for better data interfaces. ? Align stakeholders to address regulatory requirements for automation and AI, and define modernization roadmaps. ?? The future of life sciences lies in technology-driven, patient-focused innovation. But success will require cultural shifts, collaboration, and a steadfast commitment to safety, compliance, and a focus on preparing data to enable automation and AI. What themes stood out to you from the event? Let us know in the comments. A huge thanks to Life Science Integrates, facilitator Mark Buswell | NGT BioPharma Consultants and Spin's fellow panelists Elena Bonfiglioli | Microsoft, Melanie Juba | IDBS, Slawek Suchomski | Emerson, Ranjeeva Ranasinghe | GSK

?? Human or??? AI??This video shares how our science-led approach helps top biopharmas turn vast amounts of data into actionable scientific insights, and prepare data for advanced analytics and AI — but can you tell who's behind this video, human or AI? Watch and take a guess! What do you think? Let us know in the comments!

Lead clone selection and stability studies are long and involved steps in cell line development. But Scientific AI is transforming these processes. The Tetra Lead Clone Selection Assistant, powered by NVIDIA's AI models and advanced analytics, helps scientists: ? Identify high-producing, stable "super clones" ? Shorten timelines from 8 months to just 2.5 months ? Reduce risks of delays and setbacks Watch to see how you can accelerate and improve bioprocess development: https://lnkd.in/gughq9By

Scientific data is among the most fragmented and complex datasets globally, making its engineering an immense but necessary challenge. At TetraScience, we are deeply committed to liberating and unifying this data for automation, analytics, and AI applications. How are we tackling this the Tetra way? ?? Replatforming first ?? Schema & taxonomy development ?? Ontology for actionable insights ?? A Tetra community approach We’re excited to lead the transformation of scientific data engineering. Curious to learn more? Dive into our latest blog post and discover how we’re setting the standard for scientific data engineering in biopharma. Read the blog: https://lnkd.in/e7n434CH

We’re proud to announce the launch of Chromatography Insights, the first universal chromatography dashboard designed for enterprise-scale analytics in life sciences. Chromatography Insights solves the data bottleneck in the $20 billion global chromatography industry. By unifying data across all CDS from different vendors, sites, and groups, Chromatography Insights produces deeper insights, faster drug development, and more proactive QC/QA. Chromatography Insights is available immediately as part of the Tetra Scientific Data and AI Cloud. Learn more: https://lnkd.in/ebjpaK9Z

We are honored to support emerging talent and share our journey with the next generation of innovators. Last week our CEO, Patrick Grady, and our CTO, Siping Wang, had the privilege of guest lecturing at Harvard Business School alongside Satish Tadikonda and William Marks. Together, they engaged with a brilliant group of MSc, PhD, and MBA students in the?Entrepreneurship in the Life Sciences?class, exploring the transformative opportunities of Scientific AI. At TetraScience, we believe that multidisciplinary collaboration drives innovation and inspires a brighter future. #HBS #TetraScience #ScientificAI

?? Thrilled to announce TetraScience's new collaboration with NVIDIA to accelerate scientific AI adoption across life sciences! We're tackling a $1.5T industry challenge: transforming siloed scientific data into AI-driven insights and scientific use cases that can transform drug discovery, development, manufacturing, and QC. By selectively pairing NVIDIA's domain-specific AI models and compute infrastructure with the Tetra Scientific Data and AI Cloud, Tetra is creating a “factory model” approach to producing targeted, high-impact scientific AI use cases at an industrial scale across the biopharma value chain. Our initial focus includes transformative applications like lead clone selection, where we've already demonstrated the potential to reduce traditional timeframes by 80%. Quality testing can be completed twice as fast using AI to reduce deviations and accelerate investigations. AI in quality assurance can shorten lead times and enable real-time product release. Read the full announcement: https://lnkd.in/eEjBRgFb #ScientificAI #LifeSciences #Innovation #NVIDIA #TetraScience #DrugDiscovery

NVIDIA Healthcare's latest post highlights how AI is transforming healthcare and the life sciences globally. TetraScience's Lead Clone Assistant, powered by NVIDIA's VISTA-2D and Geneformer models, demonstrates what's possible when you combine AI-native scientific data with powerful compute. Read more:?https://lnkd.in/eJ3riHPE

?? Thrilled to announce TetraScience's new collaboration with NVIDIA to accelerate scientific AI adoption across life sciences! We're tackling a $1.5T industry challenge: transforming siloed scientific data into AI-driven insights and scientific use cases that can transform drug discovery, development, manufacturing, and QC. By selectively pairing NVIDIA's domain-specific AI models and compute infrastructure with the Tetra Scientific Data and AI Cloud, Tetra is creating a “factory model” approach to producing targeted, high-impact scientific AI use cases at an industrial scale across the biopharma value chain. Our initial focus includes transformative applications like lead clone selection, where we've already demonstrated the potential to reduce traditional timeframes by 80%. Quality testing can be completed twice as fast using AI to reduce deviations and accelerate investigations. AI in quality assurance can shorten lead times and enable real-time product release. Read the full announcement: https://lnkd.in/eEjBRgFb #ScientificAI #LifeSciences #Innovation #NVIDIA #TetraScience #DrugDiscovery

We had a great time at Pharma Integrates 2024. Such a collection of smart people who care about where the industry is going. TetraScience's co-founder and CTO, Siping Wang, had a chance to be on a Next-Generation Digital Technology for Pharma R&D and Manufacturing panel. The group tackled some big questions: ?? ?Will R&D and manufacturing processes become more autonomous? Yes, but it depends on the data. ???How will digital and automation technologies work together? Nicely, if organizations can nail the change management part. ???Will patients see any differences in their medicines? Definitely, in quality, quantity, and efficacy. A huge thanks to facilitator Mark Buswell | NGT BioPharma Consultants and Spin's fellow panelists Elena Bonfiglioli | Microsoft, Melanie Juba | IDBS, Slawek Suchomski | Emerson, Ranjeeva Ranasinghe | GSK What would be your answers to the above questions? Let us know in the comments. #PharmaIntegrates2024 Life Science Integrates